Cannabis Report
Home > Boards > US Listed > Biotechs >

Protagonist Therapeutics Inc (PTGX)

PTGX RSS Feed
Add PTGX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/26/2018 9:17:18 PM - Followers: 3 - Board type: Free - Posts Today: 0

Protagonist Therapeutics, Inc. (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist's primary focus is on developing oral peptide drugs that specifically target biological pathways. Its oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment. The Company's initial lead product candidates, PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), a GI disease consisting primarily of ulcerative colitis (UC) and Crohn's disease (CD). Protagonist's product candidate beyond IBD is PTG-300, which is an injectable hepcidin mimetic peptide that the Company is developing for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis (HH) and sickle cell disease (SCD).
Cannabis Report
PTGX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PTGX News: Protagonist Therapeutics Reports Granting of Inducement Award 09/19/2018 07:00:00 AM
PTGX News: Securities Registration Statement (simplified Form) (s-3) 09/07/2018 06:05:03 AM
PTGX News: Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 09/06/2018 07:01:00 AM
PTGX News: Protagonist Therapeutics Expands Intellectual Property Portfolio 09/06/2018 07:00:00 AM
PTGX News: Statement of Ownership (sc 13g) 08/20/2018 06:03:30 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!